- Home
- TMCI
as 03-25-2025 11:39am EST
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 516.6M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 445.8K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.92 - $13.24 | Next Earning Date: | 05-06-2025 |
| Revenue: | $209,357,000 | Revenue Growth: | 11.88% |
| Revenue Growth (this year): | 10.86% | Revenue Growth (next year): | 10.06% |
Stock Insider Trading Activity of Treace Medical Concepts Inc. (TMCI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scanlan Sean F. | TMCI | Chief Innovation Officer | Mar 17 '25 | Sell | $7.97 | 50,000 | $398,460.00 | 364,081 | |
| Treace John T. | TMCI | Chief Executive Officer | Mar 4 '25 | Buy | $8.73 | 60,000 | $524,064.00 | 6,796,190 |
Latest Treace Medical Concepts Inc. News
TMCI Breaking Stock News: Dive into TMCI Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
Truist Adjusts Price Target on Treace Medical Concepts to $9.50 From $10, Maintains Hold Rating
Simply Wall St.
17 days ago
John Treace Spends US$524k On Treace Medical Concepts Stock
MT Newswires
23 days ago
UBS Adjusts Treace Medical Concepts Price Target to $10 From $7.90, Maintains Neutral Rating
Simply Wall St.
25 days ago
Treace Medical Concepts Full Year 2024 Earnings: EPS Beats Expectations
MT Newswires
a month ago
Truist Securities Adjusts Price Target on Treace Medical Concepts to $10 From $8.40, Keeps Hold Rating
Thomson Reuters StreetEvents
a month ago
Q4 2024 Treace Medical Concepts Inc Earnings Call
GuruFocus.com
a month ago
Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Zacks
a month ago
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Compare TMCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMCI Treace Medical Concepts Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.